Bayland Capital
康君资本
elsewhere's corpus does not cover Bayland Capital as a subject. The only mention in the bundle is a single relation showing it as a follow-on investor in KSKD's 2026 funding round for CasCade Therapeutics, a nuclear receptor and GPCR drug R&D company . No entity card or dedicated coverage describes the fund's profile, vintage, strategy, or team.
AI-generated — may contain errors, please verify.
Bayland CapitalFund
康君资本
渲染中…
Mentioned in 4 articles
Coverage
"Deep Principle" Closes Nearly RMB 1 Billion in Total Series A Funding, Linear Capital Continues to Increase Stake | Linear Portfolio
Leading globally in AI scientist capabilities and industrial implementation.
BlueRun Ventures Leads Oversubscribed $10M+ Angel Round for Naosi Technology, Focusing on Invasive Brain-Computer Interfaces and Neural Foundation Models | BlueRun Family
AI decoding and advanced electrodes are pushing brain-computer interfaces toward real-world applications.
LogicQubit Raises Two Rounds of Funding Worth Hundreds of Millions of Yuan, Bringing Quantum Computing Into Mainstream VC Crosshairs
What's the Next Disruptive Narrative in Primary Markets?
CasCade Therapeutics Closes Nearly 500 Million Yuan Major Funding Round, Targeting Nuclear Receptor and GPCR Innovative Drug R&D
Dedicated to becoming a global leader in metabolic disease therapeutics.
